New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 16, 2014
10:34 EDTTKPYY, APRIApricus Biosciences reports Takeda accepts first shipment of Vitaros
Apricus Biosciences (APRI) announced earlier that Takeda Pharmaceuticals (TKPYY), the company's partner in the United Kingdom, has accepted the first shipment of Vitaros, Apricus' topical treatment for erectile dysfunction. Apricus CEO Richard Pascoe said, "With the commercial availability of Vitaros in the United Kingdom, Takeda is in a position to finalize its pre-launch activities in an effort to be the first Vitaros commercial partner to offer an on demand topical cream treatment for men with erectile dysfunction." Shares of Apricus are up about 16% to $2.34 in morning trading.
News For APRI;TKPYY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2015
16:55 EDTTKPYYTakeda confirms FDA approval of Ninlaro
Takeda Pharmaceutical Company Limited announced that the FDA has approved Ninlaro capsules, the first and only oral proteasome inhibitor, indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
10:52 EDTTKPYYFDA approves new oral medication to treat multiple myeloma
Subscribe for More Information
November 17, 2015
08:04 EDTAPRIStifel to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use